May 1st, 2015
Red Yeast Rice: Let’s Lower Cholesterol with Unknown Amounts of a Statin
Anthony Pearson, MD
Anthony Pearson wonders why some patients would choose unregulated “natural” cholesterol-lowering dietary supplements over safe and effective prescription statins.
July 17th, 2014
Clinical Events vs. Quality of Life: An Insider’s View of TACT
Gervasio Antonio Lamas, MD
TACT investigator Gervasio Lamas provides perspective on two new TACT papers that appear to have contradictory results.
November 19th, 2013
TACT Substudy Suggests Possible Strong Benefit for Chelation in Diabetics
Larry Husten, PHD
One year ago the results of the TACT trial were published in JAMA, sparking an enormous controversy over the propriety of publishing a trial suggesting that chelation therapy might be beneficial in people with cardiovascular disease. Chelation therapy has long been a staple of alternative medicine, but until the publication of TACT it had received […]
April 9th, 2013
The TACT Investigators Respond to Questions
Gervasio Antonio Lamas, MD, Daniel Mark, Christine Goertz, DC, PhD, Robin Boineau, M.D., M.A., Kerry L. Lee, Ph.D. and Harlan M. Krumholz, MD, SM
The publication in JAMA of the NIH’s Trial to Assess Chelation Therapy (TACT) has reignited a heated debate about the trial. The TACT investigators have generously agreed to respond to questions posed by Harlan Krumholz.
March 26th, 2013
Controversial NIH Chelation Trial Published in JAMA
Larry Husten, PHD
Final results of the troubled NIH-sponsored Trial to Assess Chelation Therapy (TACT) testing chelation therapy for coronary disease have now been published in JAMA. Last November, when the preliminary results were presented at the American Heart Association meeting, the positive finding in favor of chelation therapy surprised many observers, though the investigators and senior AHA representatives expressed considerable caution […]
November 6th, 2012
What Tack to Take in Thinking about TACT?
Reva Balakrishnan, MD, MPH
A fellow encounters a little-understood intervention and startling study results; can informal discussions with senior faculty at AHA provide insight?
November 4th, 2012
NIH Trial Gives Surprising Boost to Chelation Therapy
Larry Husten, PHD
The TACT trial finds that cardiovascular endpoints were lower with chelation therapy than placebo in patients with prior MI, but trial investigators and others have expressed considerable caution about the proper interpretation of the results.
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?